title: Influence of treatment with intranasal corticosteroids on the nasal mucosa, weight, and corticosteroid concentration in rats.
abstract: BACKGROUND
  The effect of intranasal corticosteroids on the nasal epithelium mucosa is an important parameter of treatment safety. This study was designed to examine whether treatment with topical corticosteroids in patients with allergic rhinitis causes atrophic nasal mucosal  changes, when compared with systemic corticosteroids, in rats.
  
  
  METHODS
  Male Wistar rats were treated daily during 7 weeks with topical administration with 10 microliters of normal saline (control group), 10 microliters of mometasone furoate group, 10 microliters of triamcinolone  acetonide (T group), and 8 mg/kg of daily subcutaneous injections of methylprednisolone sodium succinate (MP group). Body weight was evaluated weekly. At the end of the treatment, rats were killed by decapitation to collect blood for determination of corticosterone levels and nasal cavities  were prepared for histological descriptive analyses.
  
  
  RESULTS
  Treatment with T and MP decreased body weight. Plasma corticosterone concentration was significantly reduced by MP treatment and presented a clear tendency to decrease after T treatment. Histological changes  observed in group T included ripples, cell vacuolization, increase in the number of nuclei, and decrease in the number of cilia in the epithelial cells.
  
  
  CONCLUSIONS
  Growth and corticosterone concentration were impaired by T and MP at the same proportion, suggesting a role  of this hormone in body gain. With the exception of T, intranasal or systemic treatment with the corticosteroids evaluated in this study did not affect nasal mucosa.
authors.affiliation: Department of Ophthalmology, Otolaryngology, and Head and Neck Surgery, School of Medicine, University of São Paulo, Ribeirão Preto, SP, Brazil.
authors.forename: Danielle Morello
authors.initials: DM
authors.lastname: Park
authors.forename: Teresa Lúcia Lamano
authors.initials: TL
authors.lastname: Carvalho
authors.forename: Janete Aparecida Anselmo
authors.initials: JA
authors.lastname: Franci
authors.forename: Wilma Terezinha
authors.initials: WT
authors.lastname: Anselmo-Lima
mesh_terms: D000281:Administration, Intranasal; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000818:Animals; D018926:Anti-Allergic Agents / Q000008:administration & dosage*; D001835:Body Weight / Q000187:drug effects; D004195:Disease Models, Animal; D006801:Humans; D008297:Male; D008776:Methylprednisolone Hemisuccinate / Q000008:administration & dosage / Q000009:adverse effects; D000068656:Mometasone Furoate; D009297:Nasal Mucosa / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D011244:Pregnadienediols / Q000008:administration & dosage / Q000009:adverse effects; D051381:Rats; D017208:Rats, Wistar; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000276:immunology; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000276:immunology; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000305:Adrenal Cortex Hormones; D018926:Anti-Allergic Agents; D011244:Pregnadienediols; D000068656:Mometasone Furoate; D008776:Methylprednisolone Hemisuccinate; D014222:Triamcinolone Acetonide